Navigation Links
Evidence links anemia drugs with leukemic transformation in patients with primary myelofibrosis
Date:12/10/2007

ATLANTA -- Mayo Clinic researchers today reported the discovery of a link between erythropoiesis-stimulating agents (ESAs) and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis. The results of the retrospective study, which sought to quantify the risk factors for leukemic transformation, were presented by lead author Jocelin Huang, M.D., at the American Society of Hematologys annual meeting.

We believe this to be the first large systematic evaluation of the risk factors leading to leukemic transformation in primary myelofibrosis, says Dr. Huang, hematology researcher at Mayo Clinic. And in the process, we discovered some unexpected results.

The researchers confirmed a number of clinical and laboratory variables that appeared to correlate with leukemic transformation. Independent risk factors for development of leukemia included peripheral blood blast (immature leukemia cells) levels greater than or equal to 3 percent; and a platelet count of less than 100x109/liter (L). The more surprising findings were that specific treatments also appeared to be related to leukemic transformation. Use of ESAs or danazol (a hormone with anemia-countering properties) were linked to later development of leukemia, independent of the blast or platelet levels.

Ayalew Tefferi, M.D., principal investigator of the study, and a Mayo Clinic hematologist, cautions that the current findings are based on retrospective observation and need to be validated in properly designed prospective studies. While we cannot take these findings as an absolute, at the same time, they cannot be ignored, says Dr. Tefferi. Treatment decisions regarding the use of ESAs in patients with primary myelofibrosis should carefully be evaluated.

He also points out that ESA treatment in patients with primary myelofibrosis has the potential to cause further enlargement of the spleen (a known complication of the disease).

The study evaluated the records of 311 Mayo Clinic patients, seen with primary myelofibrosis between 1976 and 2006. Of these patients, at an average follow-up of 27 months, 27 cases (9 percent) of leukemic transformation were documented.

Other factors appeared to contribute to the development of leukemia, including anemia, leukocytosis and peripheral blood monocyte count greater than or equal to 1x109/L (both are measures of elevated white blood cells), hypercatabolic symptoms (results of excess metabolism), a splenectomy and treatment with androgens (a type of hormones). However, they were not independent predictors.


'/>"/>

Contact: Elizabeth Zimmermann
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
2. No strong evidence linking amateur boxing with long-term brain injury
3. AHRQ Announces Next Phase of Its Evidence-Based Practice Center Program
4. Vanderbilt Medical Center chosen as Evidence-based Practice Center
5. Little Evidence Silicone Breast Implants Harm Health
6. Consumers Should Demand Evidence, Not Guesswork, On Meat-Cancer Links
7. U of M study: Medicare lacks tools, incentives to enforce evidence-based coverage policies
8. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
9. Scientific evidence of the significant anti-cancer effect of milk thistle
10. Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace
11. UC Davis researchers find evidence of mature heart cell potential in embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Linfield College Online and Continuing Education ... by waiving the $50 application fee for all qualified applicants from May 1–14. Students ... Waiver option when applying . , With the RN to BSN ...
(Date:5/5/2016)... ... May 05, 2016 , ... Is the part in your hair ... a few days away, it’s a good opportunity to raise awareness about a common ... Academy of Dermatology, 40% of women experience hair loss or ‘thinning’ by the time ...
(Date:5/5/2016)... ... May 05, 2016 , ... The Wisconsin ... Lombardo, PT, DPT, MA, OCS, WCS, has been selected by the Wisconsin Physical ... The WPTA Private Practice Award is awarded annually to a member of the ...
(Date:5/4/2016)... ... , ... Mother Nature isn’t the only mom that loves the garden. Mothers ... Celebrate these women with more than just a bouquet of flowers. Give mom, or ... , Vibrant, Edible, Compact Plants from BrazelBerries: , For a gift that adds ...
(Date:5/4/2016)... ... May 04, 2016 , ... Trinity Health ... fund and implement ideas aimed at improving care and reducing readmission rates for ... our vision for Trinity Health is to drive innovation that transforms our ministry ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
(Date:5/3/2016)... 2016  While you may be familiar with watching a film or TV show in high ... or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical ... Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... 2016  Specialty Silicone Fabricators is offering teachers ... a cleanroom works. The free visual aid provides ... technology. Chris Mazelin , ... SSF enthusiastically supports the Science, Technology, Engineering and ... next generation of innovators. We want to provide ...
Breaking Medicine Technology: